Revolution Medicines (RVMD) Competitors $36.04 +0.78 (+2.22%) Closing price 03:59 PM EasternExtended Trading$35.81 -0.23 (-0.65%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RVMD vs. BNTX, INSM, SMMT, TEVA, GMAB, RDY, QGEN, MRNA, ASND, and VTRSShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Revolution Medicines vs. Its Competitors BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends. Is RVMD or BNTX more profitable? Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. BioNTech's return on equity of -1.84% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -41.78% -35.63% BioNTech -12.20%-1.84%-1.59% Do analysts recommend RVMD or BNTX? Revolution Medicines currently has a consensus price target of $68.82, indicating a potential upside of 90.93%. BioNTech has a consensus price target of $135.91, indicating a potential upside of 20.51%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Which has higher valuation & earnings, RVMD or BNTX? Revolution Medicines has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution MedicinesN/AN/A-$600.09M-$4.50-8.01BioNTech$2.88B9.42-$719.92M-$1.60-70.49 Which has more volatility and risk, RVMD or BNTX? Revolution Medicines has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Does the media favor RVMD or BNTX? In the previous week, Revolution Medicines had 3 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Revolution Medicines and 15 mentions for BioNTech. BioNTech's average media sentiment score of 0.35 beat Revolution Medicines' score of -0.11 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in RVMD or BNTX? 94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBioNTech beats Revolution Medicines on 8 of the 15 factors compared between the two stocks. Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMD vs. The Competition Export to ExcelMetricRevolution MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.74B$3.08B$5.63B$9.81BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-8.0120.6830.1125.79Price / SalesN/A329.08430.20159.26Price / CashN/A40.7837.7258.50Price / Book3.617.718.476.07Net Income-$600.09M-$54.65M$3.26B$265.11M7 Day Performance-1.71%3.95%3.56%2.90%1 Month Performance-5.20%11.46%5.97%3.99%1 Year Performance-16.18%13.04%42.70%26.92% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDRevolution Medicines3.9684 of 5 stars$36.04+2.2%$68.82+90.9%-18.0%$6.74BN/A-8.01250News CoverageEarnings ReportAnalyst RevisionBNTXBioNTech1.9691 of 5 stars$110.03+2.5%$136.58+24.1%+37.7%$25.80B$2.98B-32.366,772INSMInsmed4.0135 of 5 stars$111.24+2.3%$109.20-1.8%+64.7%$20.62B$363.71M-18.701,271Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics2.9834 of 5 stars$29.32+8.3%$34.67+18.2%+133.9%$20.10B$700K-86.23110News CoverageEarnings ReportAnalyst ForecastGap UpTEVATeva Pharmaceutical Industries3.4316 of 5 stars$15.70+2.1%$24.71+57.4%-2.9%$17.64B$16.54B-98.1336,830Positive NewsGMABGenmab A/S3.7848 of 5 stars$21.98+0.9%$37.80+72.0%-17.5%$13.97B$3.12B12.492,682Positive NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.5088 of 5 stars$13.80-1.0%$16.95+22.9%-15.5%$11.64B$334.26B20.9027,811News CoverageAnalyst RevisionQGENQiagen3.5078 of 5 stars$50.27+0.7%$49.40-1.7%+11.3%$11.10B$1.98B126.045,765Analyst DowngradeAnalyst RevisionMRNAModerna4.3882 of 5 stars$27.64+0.1%$45.61+65.0%-68.4%$10.68B$3.24B-3.675,800ASNDAscendis Pharma A/S3.4701 of 5 stars$184.15+5.5%$223.67+21.5%+52.5%$10.67B$393.54M-29.321,017Earnings ReportVTRSViatris1.2604 of 5 stars$8.94+1.5%$10.40+16.3%-12.5%$10.34B$14.74B-2.8232,000Earnings Report Related Companies and Tools Related Companies BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives GMAB Alternatives RDY Alternatives QGEN Alternatives MRNA Alternatives ASND Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVMD) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access